Who is sponsoring NCT06026605?

NCT06026605 is sponsored by Zhejiang University.

What drugs are being tested in NCT06026605?

Interventions in NCT06026605: WTX212A.

What condition does NCT06026605 study?

NCT06026605 studies Unresectable or Metastatic Advanced Solid Tumors.

Is NCT06026605 still recruiting?

NCT06026605 is currently recruiting now. Last updated 16 January 2025.

Last reviewed 2025-01-16 · How we verify

NCT06026605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors

Recruiting now EARLY_PHASE1 Last updated 16 January 2025

What this trial tests

EARLY_PHASE1 trial testing WTX212A in Unresectable or Metastatic Advanced Solid Tumors in 44 participants. Currently enrolling.

Timeline

25 August 2023

Primary endpoint
30 August 2026

30 August 2026

Quick facts

Lead sponsor	Zhejiang University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	25 August 2023
Primary completion	30 August 2026
Estimated completion	30 August 2026
Sites	1 location across China

Drugs / interventions tested

WTX212A

Conditions studied

Unresectable or Metastatic Advanced Solid Tumors — all drugs for Unresectable or Metastatic Advanced Solid Tumors →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Unresectable or Metastatic Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is a multi-center, open-label investigator-initiated clinical study (IIT) to evaluate the safety, pharmacokinetics, pharmacodynamics and effectiveness of WTX212A injection in the treatment of patients with unresectable or metastatic advanced solid tumors who failed in previous systematic therapy. The study was divided into two phases: dose escalation and dose expansion

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy.
Izzo D, Ascione L, Guidi L, Marsicano RM, et al · · 2025 · cited 22× · PMID 39759830 · DOI 10.1177/17588359241309461
Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications.
Ding J, Ding X, Liao W, Lu Z. · · 2024 · cited 10× · PMID 38188647 · DOI 10.1016/j.mtbio.2023.100913
Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial.
Nie X, Liu Y, Yao X, Zhang Q, et al · · 2026 · cited 1× · PMID 41721136 · DOI 10.1038/s43018-026-01125-2

Verify or expand the search:

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06026605 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 16 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06026605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing